CPC
MRNA icon

Congress Park Capital’s Moderna MRNA Stock Holding History

Congress Park Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,240
Closed -$645K – 122
2023
Q3 		$645K Buy
6,240
+1,640
+36% +$183K 0.34% 64
2023
Q2 		$559K Buy
4,600
+1,250
+37% +$167K 0.28% 77
2023
Q1 		$514K Buy
3,350
+195
+6% +$32.2K 0.27% 77
2022
Q4 		$567K Sell
3,155
-950
-23% -$155K 0.33% 72
2022
Q3 		$485K Buy
4,105
+750
+22% +$114K 0.28% 74
2022
Q2 		$479K Buy
3,355
+1,025
+44% +$147K 0.29% 77
2022
Q1 		$401K Buy
2,330
+1,209
+108% +$204K 0.2% 97
2021
Q4 		$285K Buy
+1,121
New +$328K 0.14% 109
2021
Q2 		– Sell
-2,412
Closed -$316K – 147
2021
Q1 		$316K Buy
+2,412
New +$350K 0.18% 101

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Congress Park Capital's MRNA Position: Q4 2023 in Review

Congress Park Capital sold out of Moderna (MRNA) in Q4 2023, closing a stake of 6,240 shares — an estimated $645K sold.

Congress Park Capital first reported a position in MRNA in Q1 2021 and held it in 9 quarters. The position peaked at $645K in Q3 2023. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Congress Park Capital reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Congress Park Capital sold 6,240 Moderna shares in Q4 2023, an estimated $645K.
  • Congress Park Capital first reported a position in Moderna in Q1 2021 and held it in 9 quarters.
  • Congress Park Capital's Moderna position peaked at $645K in Q3 2023.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Congress Park Capital's 13F filing for Q4 2023, filed 19 Jan 2024.